title: Aquaporins in primary Sjögren's syndrome: comment on the articles by Steinfeld et al.
authors.forename: Sally A
authors.initials: SA
authors.lastname: Waterman
authors.forename: Dimitra
authors.initials: D
authors.lastname: Beroukas
authors.forename: Jenny
authors.initials: J
authors.lastname: Hiscock
authors.forename: Roland
authors.initials: R
authors.lastname: Jonsson
authors.forename: Tom P
authors.initials: TP
authors.lastname: Gordon
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D051398:Aquaporin 1; D051402:Aquaporin 5; D020346:Aquaporins / Q000378:metabolism; D001789:Blood Group Antigens; D015536:Down-Regulation; D006801:Humans; D000069285:Infliximab; D008565:Membrane Proteins; D012470:Salivary Glands, Minor / Q000187:drug effects / Q000378:metabolism* / Q000473:pathology; D012859:Sjogren's Syndrome / Q000188:drug therapy*; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000502:physiology
chemical_list: C496020:AQP1 protein, human; C496036:AQP5 protein, human; D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D051402:Aquaporin 5; D020346:Aquaporins; D001789:Blood Group Antigens; D008565:Membrane Proteins; D014409:Tumor Necrosis Factor-alpha; D051398:Aquaporin 1; D000069285:Infliximab